Hypertension pulmonaire

Pulmonary hypertension (PH) is a complex disease with poor prognosis. In current recommendations, PH is classified in five groups and one subgroup. In group 3, PH associated with chronic obstructive pulmonary disease (COPD) is a common form. It is associated with a high mortality due to right ventricular dysfunction. The specific pharmacological treatment is proposed principally to patients in group 1. In the treatment of PH, inclusion in registries, early diagnosis and improved functional class are the main objectives. During the European Respiratory Society Congress in Amsterdam in 2011, this topic has been discussed via several communications.